Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas

T. De Pas, G. Curigliano, G. Masci, C. Catania, A. Comandone, C. Boni, A. Tucci, O. Pagani, E. Marrocco, F. De Braud

Research output: Contribution to journalArticle

Abstract

Purpose: To determine whether a prolonged 12-day continuous infusion allows the administration of high-dose ifosfamide (IFO) with an acceptable toxicity profile when combined with full-dose doxorubicin (Adriamycin®; ADM) as first-line chemotherapy in patients with advanced soft tissue sarcomas. Patients and methods: Escalating doses of continuous infusion IFO (8-15 g/m 2) given on days 1 to 12 in combination with ADM 75 mg/m 2 given on day 8 and prophylactic granulocyte colony-stimulating factor support were administered every 4 weeks to 35 chemonaïve patients with advanced soft tissue sarcomas. Results: The maximum tolerated dose was IFO 15 g/m 2. Hematological toxicity was the main dose-limiting toxicity and was dose dependent. Furthermore, thrombocytopenia was cumulative. Grade 4 (WHO) neutropenia and thrombocytopenia were recorded in 48% and 14% of courses, respectively. Eight patients experienced febrile neutropenia. A partial response was observed in 16 out of 30 assessable patients [53%, 95% confidence interval (CI) 25-63]; median time to progression was 25 weeks (range 4-91). Conclusions: This study proved that a prolonged 12-day continuous infusion allows an increase in the total IFO dose that can be safely combined with ADM. A multicentric phase II study by the Italian Sarcoma Group to assess its antitumor activity is currently ongoing in patients with advanced soft tissue sarcomas.

Original languageEnglish
Pages (from-to)161-166
Number of pages6
JournalAnnals of Oncology
Volume13
Issue number1
DOIs
Publication statusPublished - 2002

Keywords

  • Chemotherapy
  • Continuous infusion
  • High dose
  • Ifosfamide
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas'. Together they form a unique fingerprint.

  • Cite this